scholarly journals Intratumoral injection of hydrogel-embedded nanoparticles enhances retention in glioblastoma

Nanoscale ◽  
2020 ◽  
Vol 12 (46) ◽  
pp. 23838-23850
Author(s):  
Giulia Brachi ◽  
Javier Ruiz-Ramírez ◽  
Prashant Dogra ◽  
Zhihui Wang ◽  
Vittorio Cristini ◽  
...  

Intratumoral drug delivery is a promising approach for the treatment of glioblastoma multiforme (GBM).

2020 ◽  
Vol 21 ◽  
Author(s):  
Sayed Md Mumtaz ◽  
Gautam Bhardwaj ◽  
Shikha Goswami ◽  
Rajiv Kumar Tonk ◽  
Ramesh K. Goyal ◽  
...  

: The Glioblastoma Multiforme (GBM; grade IV astrocytoma) exhort tumor of star-shaped glial cell in the brain. It is a fast-growing tumor that spreads to nearby brain regions specifically to cerebral hemispheres in frontal and temporal lobes. The etiology of GBM is unknown, but major risk factors are genetic disorder like neurofibromatosis and schwanomatosis which develop the tumor in the nervous system. The management of GBM with chemo-radio therapy leads to resistance and current drug regimen like Temozolomide (TMZ) is less efficacious. The reasons behind failure of drugs are due to DNA alkylation in cell cycle by enzyme DNA guanidase and mitochondrial dysfunction. Naturally occurring bio-active compounds from plants known as phytochemicals, serve as vital sources for anti-cancer drugs. Some typical examples include taxol analogs, vinca alkaloids such as vincristine, vinblastine, podophyllotoxin analogs, camptothecin, curcumin, aloe emodin, quercetin, berberine e.t.c. These phytochemicals often act via regulating molecular pathways which are implicated in growth and progression of cancers. However the challenges posed by the presence of BBB/BBTB to restrict passage of these phytochemicals, culminates in their low bioavailability and relative toxicity. In this review we integrated nanotech as novel drug delivery system to deliver phytochemicals from traditional medicine to the specific site within the brain for the management of GBM.


Author(s):  
Ana C. Marques ◽  
Paulo J. Costa ◽  
Sérgia Velho ◽  
Maria H. Amaral

Pharmaceutics ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 860
Author(s):  
Raneem Jnaidi ◽  
António José Almeida ◽  
Lídia M. Gonçalves

Glioblastoma multiforme (GBM) is the most common and malignant type of brain tumor. In fact, tumor recurrence usually appears a few months after surgical resection and chemotherapy, mainly due to many factors that make GBM treatment a real challenge, such as tumor location, heterogeneity, presence of the blood-brain barrier (BBB), and others. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) represent the most promising carriers for therapeutics delivery into the central nervous system (CNS) owing to their inherent ability to cross the BBB. In this review, we present the main challenges in GBM treatment, a description of SLNs and NLCs and their valuable role as drug carriers in GBM treatment, and finally, a detailed description of all modification strategies that aim to change composition of SLNs and NLCs to enhance treatment outcomes. This includes modification of SLNs and NLCs to improve crossing the BBB, reduced GBM cell resistance, target GBM cells selectively minimizing side effects, and modification strategies to enhance SLNs and NLCs nose-to-brain delivery. Finally, future perspectives on their use are also be discussed, to provide insight about all strategies with SLNs and NLCs formulation that could result in drug delivery systems for GBM treatment with highly effective theraputic and minimum undesirable effects.


2020 ◽  
Vol 2 (10) ◽  
pp. 4498-4509
Author(s):  
Majed Alghamdi ◽  
Filippo Chierchini ◽  
Dimitri Eigel ◽  
Christian Taplan ◽  
Thomas Miles ◽  
...  

Soft and flexible poly(ethylene glycol)-based nanotubes load doxorubicin for controlled release to glioblastoma multiforme.


Drug Research ◽  
2020 ◽  
Author(s):  
Md. Habban Akhter ◽  
Md. Rizwanullah ◽  
Javed Ahmad ◽  
Saima Amin ◽  
Mohammad Zaki Ahmad ◽  
...  

AbstractGlioblastoma multiforme (GBM) is the most aggressive and fatal CNS related tumors, which is responsible for about 4% of cancer-related deaths. Current GBM therapy includes surgery, radiation, and chemotherapy. The effective chemotherapy of GBM is compromised by two barriers, i. e., the blood-brain barrier (BBB) and the blood tumor barrier (BTB). Therefore, novel therapeutic approaches are needed. Nanoparticles are one of the highly efficient drug delivery systems for a variety of chemotherapeutics that have gained massive attention from the last three decades. Perfectly designed nanoparticles have the ability to cross BBB and BTB and precisely deliver the chemotherapeutics to GBM tissue/cells. Nanoparticles can encapsulate both hydrophilic and lipophilic drugs, genes, proteins, and peptides, increase the stability of drugs by protecting them from degradation, improve plasma half-life, reduce adverse effects and control the release of drugs/genes at the desired site. This review focussed on the different signaling pathways altered in GBM cells to understand the rationale behind selecting new therapeutic targets, challenges in the drug delivery to the GBM, various transport routes in brain delivery, and recent advances in targeted delivery of different drug and gene loaded various lipidic, polymeric and inorganic nanoparticles in the effective management of GBM.


2020 ◽  
Vol 31 (3) ◽  
pp. S192
Author(s):  
D. Leach ◽  
N. Muñoz ◽  
C. Dupuis ◽  
M. Williams ◽  
K. Dixon ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document